Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Genique Stanislaus"'
Autor:
Seyyedeh S Saneeymehri, Jennifer Tobin, Matthew J Newman, Ali McBride, Caroline J. Hoang, Valerie Relias, Genique Stanislaus, Shilpa Paul, Joanne C Ryan, Ilene Galinsky
Publikováno v:
Journal of Oncology Pharmacy Practice
Objective Acute myeloid leukemia (AML) is primarily a disease of older adults. These patients may not be candidates for intensive treatment, and there has been an ongoing need for treatment options for this group. We review the use of glasdegib, a he
Autor:
Relias, Valerie, McBride, Ali, Newman, Matthew J, Paul, Shilpa, Seyyedeh Saneeymehri, Genique Stanislaus, Tobin, Jennifer, Hoang, Caroline J, Ryan, Joanne C, Galinsky, Ilene
Supplemental material, sj-pdf-1-opp-10.1177_1078155220973737 for Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists by Valerie Relias, Ali McBride, Matthew J Newman, Shi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fb318e9612d1c4109d13503bafbb799
Autor:
Grace Perry, Genique Stanislaus, Joelle Gagnon, Yen-Hong Kuo, Danielle Marcotulli, Maritess Aviador, James K. McCloskey, Jamie Koprivnikar, Elizabeth Jones
Publikováno v:
Blood. 132:2703-2703
Background: Blinatumumab (B), a bi-specific T-cell engaging CD3-CD19 antibody construct, has shown significant activity in patients (pts) with B-cell acute lymphoblastic leukemia (B-ALL). Despite this improvement, uncertainties remain regarding the o
Publikováno v:
Blood. 132:5448-5448
Abstract Background: The development of tyrosine kinase inhibitors (TKIs) has dramatically changed the landscape of chronic myelogenous leukemia (CML) treatment. Dosing of TKIs is based on the phase of disease at presentation, but is not altered base
Autor:
Samantha Depadova, Genique Stanislaus, James K. McCloskey, Stuart L. Goldberg, Stefan Faderl, Jamie Koprivnikar, Marshall McKenna, Tracy Andrews
Publikováno v:
Blood. 128:4017-4017
Background: Pts with AML-Mo, often present with leukocytosis and aggressive clinical features such as extramedullary involvement and coagulation abnormalities. Frequently the clinical presentation resembles a hyperinflammatory phenotype. This often l
Autor:
Amy L. Davidow, Genique Stanislaus, Stefan Faderl, David Ray, Samantha Depadova, James K. McCloskey, Stuart L. Goldberg, Jamie Koprivnikar, Christina Howlett
Publikováno v:
Blood. 128:5174-5174
OBJECTIVE: According to standard protocol, the earliest post treatment marker of response following intensive induction therapy in patients with AML is a D14 marrow biopsy. Some controversy has surrounded this practice. This study aims to evaluate re
Autor:
James K. McCloskey, Marshall McKenna, Jamie Koprivnikar, Samantha Depadova, Stuart L. Goldberg, Genique Stanislaus, Stefan Faderl
Publikováno v:
Blood. 128:5242-5242
Background: Cytogenetic and molecular abnormalities are the backbone of risk stratification for pts with AML/MDS. Yet, the current stratification systems still fail to identify some pts at high risk for treatment failure. TP53 mutations have been lin
Autor:
Stuart L. Goldberg, Stefan Faderl, Genique Stanislaus, James K. McCloskey, Jamie Lynn Koprivnikar
Publikováno v:
Journal of Clinical Oncology. 34:e18543-e18543
e18543Background: Imatinib revolutionized the treatment of CML demonstrating improved survival and durable response to treatment. Earlier and deeper response rates were observed with dasatinib and ...
Autor:
James K. McCloskey, Stefan Faderl, Yucai Wang, Jamie Koprivnikar, Genique Stanislaus, Stuart L. Goldberg
Publikováno v:
Journal of Clinical Oncology. 34:e18544-e18544
e18544Background: Dosing of TKIs is standardized and is not altered based on BSA, sex, or other patient characteristics. Long-term data on the effects of dose-reduction of TKI therapy based on toxi...
Autor:
Genique Stanislaus, James K. McCloskey, Themba Nyirenda, Stefan Faderl, Stuart L. Goldberg, Jamie Koprivnikar, Christina Howlett
Publikováno v:
Blood. 126:5168-5168
Background: Imatinib revolutionized the treatment of chronic myelogenous leukemia (CML) demonstrating improved survival and durable response to treatment. Earlier and deeper response rates were observed with dasatinib and nilotinib in the front line